Experts discuss ways to expand contraceptive choice, increase access to LARCs

2013 statement from the Bellagio Group on LARCs

In November 2013 at the International Conference on Family Planning in Addis Ababa, Ethiopia, the Population Council convened the third meeting of international experts to discuss ways to expand contraceptive choice and accelerate progress toward the Millennium Development Goal of universal access to reproductive health services by increasing access to highly effective, long-acting, reversible contraceptives (LARCs).

The Bellagio Group shares a commitment to leadership in increasing access and choice in contraceptive information, services, and supplies. Participants include service providers, donor representatives, researchers, procurement specialists, manufacturers, and public health specialists.

This commitment is grounded in the belief that access to high-quality, effective, and voluntary contraceptive information, services, and supplies improves health expands opportunities, and improves family and community welfare. LARCs are a vital part of the method mix, but are often inaccessible to many women, especially adolescent girls. Working together, the global community and national public, private, and civil society partners must ensure that LARCs are fully available alongside other contraceptive methods so that universal access is achieved through informed choice, voluntarism, and equity.

In Addis Ababa, the Bellagio Group reached a consensus on the following statement and recommendations for action.

In recognition of the theme of the 2013 International Conference on Family Planning, Full Access, Full Choice, the Bellagio Group reaffirms its commitment to expanding access to highly effective, long-acting, reversible contraception for women and adolescent girls within the full range of contraceptive choice.

The Bellagio Group first convened in 2012 when it called for greater access to LARCs within a contraceptive framework that advances rights, promotes quality of care, assures equity, and responds to the needs of the most vulnerable populations in developing countries. Since then, significant progress has been made, including:

  1. An increased commitment to the rights and voices of women and adolescent girls within national family planning and reproductive health programs.
  2. Greater priority placed on equity in contraceptive access and ensuring that young people and those who are the most marginalized and live in the most difficult circumstances are given the greatest attention and care.
  3. Expanded access to a wider range of contraceptive methods and related services (e.g. counseling, insertion, and removal) through efforts to reduce costs and increase the broad availability of LARCs as part of a comprehensive range of method choices.
  4. Expanded access to various types of healthcare providers in the public and private sectors who have acquired the skills needed to deliver effective contraceptive options to women and adolescent girls.
  5. More effective integration of LARCs into commodity supply chains and greater awareness of and demand for all contraceptive choices.

Recommendations for Action

Despite progress to date, LARCs remain out of reach for many women and adolescent girls-especially the poorest and most marginalized. The Bellagio Group asserts that if all women, men, and young people do not have a full and informed choice of contraceptive options, they do not have full access.

To expand choice and access, the Bellagio Group calls on global and national family planning communities to focus on the following priority areas:

  1. Ensuring that all women, men, and young people have equal access to the full array of short-term, long-acting, permanent, and emergency method choices for delaying, spacing, and limiting pregnancies.
  2. Educating women, adolescents, and their partners, providers, and policymakers about the potential utility of LARCs as high-quality, effective, and voluntary post-partum and post-abortion contraceptive options.
  3. Enabling full choice of contraceptive methods for young women by ensuring that LARCs are included in counseling on contraceptive options and that products and trained providers are available to young women choosing this option in both public and private settings.
  4. Identifying, evaluating, and implementing innovative strategies for financing and enhancing the sustainability of contraceptive products and services.
  5. Employing a total market approach with public, commercial, and non-for-profit providers to give women, men, and young people full access to affordable and acceptable contraceptive options.
  6. Developing rights-based and total market metrics that are accepted and used nationally and globally to ensure protection of rights, enhance equity, chart progress toward universal access, and hold policymakers accountable for creating an environment conducive to meeting the reproductive health needs of all.

 

The Bellagio Group will continue to operate as a think-tank for effectively tapping into a wealth of knowledge shared by respected experts. The group strives to find innovative solutions that expand contraceptive choice and accelerate universal access to reproductive health services by increasing availability of LARCs.

Bellagio Group Members:

  • Sabaratnam Arulkumaran, FIGO
  • Gloria Asare Ghana Health Service, Ghana
  • Ian Askew*, Population Council
  • Pam Barnes*, EngenderHealth
  • Aron Betru*, Pledge Guarantee for Health
  • Paul Blumenthal*, Stanford University
  • Campbell Bright*, UNFPA
  • Klaus Brill*, Bayer Healthcare
  • Julia Bunting*, IPPF
  • Peter Donaldson*, Population Council - Chair
  • Eric Dupont, UNFPA
  • Anibal Fa-ndes, FIGO
  • Chastain Fitzgerald*, WomanCare Global
  • Turkiz Gokgol, Susan T. Buffett Foundation
  • Victoria Hale, Medicines360
  • Karl Hofmann*, PSI
  • Roy Jacobstein*, EngenderHealth
  • Koen Kruytbosch*, Merck/MSD
  • Julia Lowe, Bill & Melinda Gates Foundation
  • Baker Maggwa*, FHI360
  • Roland Edgar Mhlanga, Ministry of Health, South Africa
  • Nomi Fuchs-Montgomery*, MSI
  • Basab Mukherjee*, FIGO
  • Beatrice Mutali*, Merck/MSD
  • Saundra Pelletier, WomanCare Global
  • C.N. Purandare*, FIGO
  • Scott Radloff*, Gates Institute
  • Kshama Roberts*, Merck/MSD
  • Jill Sheffield*, Women Deliver
  • John Skibiak*, Reproductive Health Supplies Coalition
  • Jeff Spieler*, USAID
  • Harriet Stanley*, EngenderHealth
  • Alan Staple, The Clinton Foundation Health Access Initiative
  • Sally Stephens*, Medicines360
  • John Townsend*, Population Council
  • James Trussell, Princeton University
  • Shahida Zaidi, Former FIGO Vice President

*Denotes those who participated in the third meeting of the Bellagio Group in Addis Ababa, Ethiopia.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
FDA strengthens AI regulation to ensure patient safety and innovation in healthcare